XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Nature of Business - Additional Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Cash, cash equivalents and short-term investments $ 34,200,000    
Net loss (19,288,000) $ (3,630,000) [1]  
Accumulated deficit [2] (130,995,000)   $ (111,707,000)
Acceleration of stock awards 10,500,000    
Severance and termination benefit expense 5,700,000    
Consideration Transferred 29,400,000    
Total operating expenses $ 22,340,000 $ 4,211,000  
CalciMedica      
Percentage of ownership of common stock 72.00%    
Graybug      
Severance and termination benefit expense $ 16.2    
Percentage of ownership of common stock 28.00%    
Convertible Debt [Member]      
Gross proceeds from convertible debt $ 8,600,000    
Preferred and Common stock [Member]      
Total Gross Proceeds $ 111,700,000    
[1]

(1) Retroactively restated for the reverse recapitalization as described in Note 2.
[2]

(1) Retroactively restated for the reverse recapitalization as described in Note 2.